Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00287872 · OUTCOME

The Time to Response

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma · Source last updated 2018-03-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
1-6 months

Groups in this outcome

Bortezomib and Thalidomide

The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide. bortezomib thalidomide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib and Thalidomide22

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bortezomib and Thalidomide2Not reported0.55.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.5
        upper Limit
        5.8
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide. bortezomib thalidomide
    id
    OG000
    title
    Bortezomib and Thalidomide
param Type
MEDIAN
reporting Status
POSTED
time Frame
1-6 months
title
The Time to Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice